• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»AACR 2026 (Page 4)

How Orum Therapeutics plans to solve GSPT1 toxicity with a DAC approach in AML

By Pallavi Madhiraju on March 19, 2026   Pharma & Biotech  

How Orum Therapeutics plans to solve GSPT1 toxicity with a DAC approach in AML

Orum Therapeutics presents ORM-1153 DAC preclinical data at AACR 2026, including primate safety findings ahead of a planned AML IND filing. Read the analysis.

How Exact Sciences is building a multi-platform cancer diagnostics case at AACR 2026

By Pallavi Madhiraju on March 19, 2026   Medical Devices & Diagnostics  

How Exact Sciences is building a multi-platform cancer diagnostics case at AACR 2026

Exact Sciences presents Oncodetect MRD and Cancerguard MCED data at AACR 2026. Analysis of what the new TNBC and multi-biomarker classifier findings mean for clinical adoption.

Can Synthekine’s STK-012 overcome immunotherapy resistance in first-line NSCLC patients?

By Pallavi Madhiraju on March 18, 2026   Pharma & Biotech  

Can Synthekine’s STK-012 overcome immunotherapy resistance in first-line NSCLC patients?

Can STK-012 overcome immunotherapy resistance in lung cancer? Explore AACR 2026 data and what it means for IL-2 precision therapies.

Could five-year survival data position KIMMTRAK as a durable standard in uveal melanoma care

By Soujanya Ravi on March 17, 2026   Pharma & Biotech  

Could five-year survival data position KIMMTRAK as a durable standard in uveal melanoma care

Discover how Immunocore’s five-year KIMMTRAK data could reshape survival expectations in metastatic uveal melanoma. Read the full analysis.

« Previous 1 2 3 4

Recent Posts

  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes